Impact of 18F-Choline PET/CT in Prostate Cancer Patients with Biochemical Recurrence: Influence of Androgen Deprivation Therapy and Correlation with PSA Kinetics
- 4 April 2013
- journal article
- clinical trial
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 54 (6), 833-840
- https://doi.org/10.2967/jnumed.112.110148
Abstract
We evaluated the potential of 18F-fluoromethyldimethyl-2-hydroxyethyl-ammonium (FCH) PET/CT in the detection of recurrent disease or distant metastases and correlated its diagnostic accuracy with prostate-specific antigen (PSA) levels in prostate cancer patients with biochemical evidence of recurrence. Furthermore, the influences of androgen deprivation therapy (ADT) and its duration on 18F-FCH PET were assessed in this study. Methods: This prospective study included 250 prostate cancer patients with PSA relapse who underwent 18F-FCH PET/CT. At the time of 18F-FCH PET/CT imaging, the mean PSA level was 46.9 ± 314.7 ng/mL and 55.2% (138/250) of patients were receiving ADT. Overall, ADT was performed on 67.2% (168/250) of patients after initial treatment. Imaging was performed on an integrated PET/CT system. Acquisition started 1 min after intravenous injection of 18F-FCH (4.07 MBq/kg of body weight) with dynamic PET images in the pelvic region during 8 min (1 min/frame) followed by a static semi–whole-body acquisition. The final diagnosis of positive PET lesions was based on histopathology or a consensus of clinical findings, additional imaging, or follow-up imaging modalities. Results: 18F-FCH PET/CT was able to correctly detect malignant lesions in 74% (185/250) of patients but was negative in 26% (65/250). In 28% of patients, only 1 lesion was detected (69/250); from these, 65.2% (45 patients) had a local recurrence, 18.8% (13 patients) a single lymph node, and 15.9% (11 patients) a solitary bone metastasis. The sensitivity of the 18F-FCH PET was significantly higher (P = 0.001) in patients with ongoing ADT (85%; confidence interval, 80%–91%) than in patients without ADT (59.5%; confidence interval, 50%–69%). 18F-FCH PET sensitivity was 77.5%, 80.7%, 85.2%, and 92.8% for the trigger PSA levels of more than 0.5, 1.0, 2.0, and 4.0 ng/mL, respectively. Scan sensitivity was 33% in patients with a trigger PSA level of less than 0.3 ng/mL and 77% in patients with a trigger PSA level of greater than 0.3 ng/mL, respectively (P = 0.001). Using a binary logistic regression analysis model, we showed trigger PSA and ADT to be the only significant predictors of positive PET findings. Conclusion: 18F-FCH PET/CT proved its potential as a noninvasive 1-stop diagnostic modality enabling us to correctly detect occult disease in 74% of patients and to differentiate localized from systemic disease. In patients with biochemical recurrence, it also guides to an optimal treatment approach after initial treatment. Trigger PSA and ADT are the 2 significant predictors of 18F-FCH–positive PET lesions. ADT seems not to impair 18F-FCH uptake in hormone-refractory prostate cancer patients.This publication has 34 references indexed in Scilit:
- Imaging Prostate Cancer: A Multidisciplinary PerspectiveRadiology, 2007
- [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patientsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2006
- The Role of Fluorodeoxyglucose, 18F-Dihydroxyphenylalanine, 18F-Choline, and 18F-Fluoride in Bone Imaging with Emphasis on Prostate and BreastSeminars in Nuclear Medicine, 2006
- Fluorocholine PET/CT in Patients with Prostate Cancer: Initial ExperienceRadiology, 2005
- Cancer Statistics, 2005CA: A Cancer Journal for Clinicians, 2005
- BASELINE STAGING OF NEWLY DIAGNOSED PROSTATE CANCER: A SUMMARY OF THE LITERATUREJournal of Urology, 2004
- Advances in imaging in the postoperative patient with a rising prostate-specific antigen levelSeminars in Oncology, 2003
- Value of [ 11 C]choline-Positron Emission Tomography for Re-Staging Prostate Cancer: A Comparison With [ 18 F]fluorodeoxyglucose-Positron Emission TomographyJournal of Urology, 2003
- Natural History of Progression After PSA Elevation Following Radical ProstatectomyJAMA, 1999
- Hazard rates for progression after radical prostatectomy for clinically localized prostate cancerUrology, 1997